The administration has moved to stop federal Medicaid and CHIP funding for puberty blockers, cross-sex hormones, and surgical procedures for minors, citing concerns about safety, a lack of reliable clinical benefit, and taxpayer responsibility.
The Centers for Medicare & Medicaid Services announced that Medicaid will no longer pay for child sex change hormones and surgeries, and the Children’s Health Insurance Program will follow suit. Officials framed the change as protecting kids from what they described as experimental, life-altering interventions with long-term risks. The policy shift aims to reorient federal dollars toward treatments the agencies consider evidence-based and safer for minors.
CMS Administrator Dr. Mehmet Oz explained the decision by pointing to a broader principle. He said the move reflects the Administration’s “commitment to protect children from experimental and life-altering sex-rejecting procedures that carry serious long-term health risks and lack sufficiently reliable evidence of clinical benefit.” That language sets the tone for a nationwide pause in federally funded physical interventions for minors.
The list of procedures excluded from funding includes cross-sex hormones, puberty blockers and sex-change surgical operations for children. Officials cited a body of reviews and research that, in their view, fails to show reliable clinical benefit and raises alarms about lasting harm. Among the potential consequences, HHS and CMS warned about “irreversible damage, including infertility, impaired sexual function, diminished bone density, altered brain development, and other lasting physiological effects.”
https://x.com/RapidResponse47/status/2087199076156584062
Dr. Oz went further in summing up the policy rationale, saying, “Children deserve our protection, not experimental interventions that pose serious risks and convey no proven benefits. By cutting off federal funds for these sex-rejecting procedures, we’re following the science, saving taxpayer dollars, and, most importantly, protecting children from potentially irreversible harm so they can truly flourish.” Those words underline the administration’s emphasis on safety and fiscal accountability.
CMS said it relied heavily on the 2024 Cass Review from the United Kingdom, led by Dr. Hilary Cass, which questioned much of the clinical evidence supporting gender-affirming medical interventions for minors. That report found that many studies were non-clinical and flagged major limits in claiming mental health benefits. Officials used those findings to justify narrowing the scope of what federal health dollars will cover.
The agencies made clear that Medicaid and CHIP will continue to fund mental health services related to gender dysphoria, including counseling, psychotherapy, and psychiatric evaluation. What will change is the coverage of physical, so-called affirming medical treatments for minors, which will no longer receive federal support. The decision attempts to separate psychological care from procedures the administration views as experimental for children.
Implementation will not be instantaneous; the administration plans a phased approach that allows current patients a limited grace period. Those already receiving covered treatments will be grandfathered for six months past the enactment date, giving families and providers a brief transition window. Beyond that period, federal reimbursement for the listed physical interventions will cease.
Supporters of the policy frame it as a defense of children and taxpayers against what they call the spread of woke medical practices into federal programs. They argue the change restores common-sense guardrails and redirects limited public funds to care with stronger evidence. Critics predict legal and political fights, but the administration appears prepared to stand on the science and fiscal stewardship as its justification.
The Trump Administration is drawing a clear line: America’s children will not be subjected to life-altering interventions on the taxpayer’s dime without reliable evidence of safety and clinical benefit. Under the leadership of Secretary Kennedy, federal health care dollars will support evidence-based care that protects children and puts their long-term health first. American taxpayers should never be forced to finance interventions when the evidence of benefit is insufficient and the potential consequences for children can be serious and irreversible.
